tbuckley/cabot-search huggingface dataset:
Twenty Years Mark Success Against Tobacco Use
Authors: C. Vanchieri, J. Waalen
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Twenty Years Mark Success Against Tobacco Use Get access Cori Vanchieri, Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar Jill Waalen Jill Waalen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 7, 3 April 1991, Pages 466–468, https://doi.org/10.1093/jnci/83.7.466 Published: 03 April 1991
Abstract 2376: Endothelial cells acquire abnormalities by factors from tumor cells
Authors: Akiyama Kosuke, Noritaka Ohga, Yasuhiro Hida, Tomoshige Akino, Naoya Hirata, Kurosu Takuro, Shuhei Ishikawa, Miyako Kondo, Nako Maishi, Taisuke Kawamoto, Nobuo Inoue, Masanobu Shindoh, Kyoko Hida
Journal: Cancer Research (2010)

Abstract Recently, it has been reported that tumor microenvironment is important for tumor progression and metastasis. We have reported that tumor endothelial cells (TECs) differ from their normal counterparts, in many aspects. For example, TECs upregulate several genes, have cytogenetical abnormalities and respond differently to the growth factors such as epidermal growth factor receptor (EGFR) or some anticancer drugs (Hida et al., Cancer Res 2004, Cancer Sci 2008). In this study, we focused on the interaction between tumor cells and endothelial cells to address the mechanism of TEC abnormality. We demonstrate that cultured conditioned medium (CM) from melanoma cells cause several phenotypic changes in Human Microvascular Endothelial Cells (HMVEC). The cell proliferation of HMVEC was stimulated by melanoma CM. Furthermore, the expression level of Multi Drug Resistance Gene (MDR) was upregulated by melanoma CM treatment and HMVEC got less sensitive to Paclitaxel. It was suggested that some factors released from melanoma cause abmormalities in HMVEC phenotype. The study to elucidate mechanisms of these results are ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2376.
ACUTE KIDNEY INJURY WITH TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE U.S.: CAN WE REDUCE THE RISK?
Authors: Charles Brooks, Jennie Z. Ma, Sandra G. Burks, Rachel M. Simon, Amanda Stebbins, Gorav Ailawadi, Michael Ragosta, D. Scott Lim, John Kern, Irving Kron
Journal: Journal of the American College of Cardiology (2015)
Income, Life Expectancy, and Community Health
Authors: J. Michael McGinnis
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
Authors: Anita D'Souza, Martha Lacy, Morie Gertz, Shaji Kumar, Francis Buadi, Suzanne Hayman, David Dingli, Steven Zeldenrust, Robert Kyle, Stephen Ansell, David Inwards, Patrick Johnston, Ivana Micallef, Luis Porrata, Mark Litzow, Dennis Gastineau, William Hogan, Angela Dispenzieri
Journal: Blood (2012)
P387 REGULATORY T-CELL IMPAIRMENT IN AUTOIMMUNE LIVER DISEASE IS LINKED TO AN ABERRANTLY HIGH EXPRESSION OF CD127
Authors: R. Liberal, C.R. Grant, J. Cardone, Y. Ma, M.A. Heneghan, G. Mieli-Vergani, D. Vergani, M.S. Longhi
Journal: Journal of Hepatology (2014)
Tc-99m MDP Uptake in Uterine Leiomyoma
Authors: ANA B. M. J. TEIXEIRA, ELBA C. S. C. ETCHEBEHERE, DANIELA C. CARVALHO, MARLA C. M. SOUSA, ALLAN O. SANTOS, MARIANA C. L. LIMA, CELSO D. RAMOS, EDWALDO E. CAMARGO
Journal: Clinical Nuclear Medicine (2000)

TEIXEIRA, ANA B. M. J.; ETCHEBEHERE, ELBA C. S. C.; CARVALHO, DANIELA C.; SOUSA, MARLA C. M.; SANTOS, ALLAN O.; LIMA, MARIANA C. L.; RAMOS, CELSO D.; CAMARGO, EDWALDO E. Author Information
Abstract 1264: Mutated CD80 may facilitate T-cell activation by inhibiting PDL1-PD1 suppression and by costimulating.
Authors: Sonia P. Dalal, Samuel Haile, Preethi Somasundaram, Suzanne Ostrand-Rosenberg
Journal: Cancer Research (2013)

Abstract CD80 functions as a costimulatory signal to activate T cells when it binds to CD28 or as an apoptotic signal when it binds to CTLA4. We recently identified another function for CD80 and showed that co-expression of CD80 by Program Death Ligand-1+ (PDL1+) human tumor cells prevents PDL1 binding to its receptor PD1 on activated T cells, and enhances activation of tumor-reactive T cells. To distinguish if CD80 is facilitating T cell activation by preventing PDL1-PD1 interactions and/or by functioning as a costimulatory molecule, we have generated a recombinant CD80 molecule that does not bind to CD28. Since we hypothesize that CD80 may be a therapeutic for inhibiting tumor-mediated immune suppression via PDL1-PD1 interactions, the recombinant CD80 is also designed to not interact with CTLA4. Using site directed mutagenesis we generated CD80 with the following mutations: H96A, L97A, and E99A (CD8096,97,99). CD28 and CTLA4 bind to 35.3% and 37.4%, respectively, of tumor cells expressing wild type CD80. In contrast, only 1.2% and 1.4% of tumor cells expressing CD8096,97,99 bind CD28 and CTLA4, respectively, demonstrating that the mutant CD80 does not bind to CD28 or CTLA4. Previous studies demonstrated that CD80 prevents PDL1-PD1 interactions by binding to PDL1 and obscuring its detection. Only 7.05% of CD8096,97,99 mutants have detectable PDL1 (vs. 98% of untransfected parental human tumor cells), demonstrating that the CD8096,97,99 mutant does not bind CD28 or CTLA4, but retains the ability to inhibit PDL1-PD1 interactions. We are also generating a soluble form of CD8096,97,99 (sCD8096,97,99) that could be administered to cancer patients to prevent tumor cell-mediated PDL1 immune suppression. The construct for the soluble form was generated by ligating the two extracellular domains of CD80 containing the 96,97,99 mutations to the Fc region of human IgG1, followed by incorporation into the Pet21a+ plasmid containing the T7 promoter. Recombinant protein will be isolated from transformed E. coli using a protein G affinity column, and tested in functional experiments with PDL1+ tumor cells to determine if CD80 increases T-cell activation by inhibiting PDL1-PD-1 immune suppression and/or by facilitating costimulation. This work was funded, in part, by grants from the HHMI Precollege and Undergraduate Science Education Program (52006949), CBI (T32 GM066706), and NIH (R01CA84232 and RO1CA115880). Citation Format: Sonia P. Dalal, Samuel Haile, Preethi Somasundaram, Suzanne Ostrand-Rosenberg. Mutated CD80 may facilitate T-cell activation by inhibiting PDL1-PD1 suppression and by costimulating. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1264. doi:10.1158/1538-7445.AM2013-1264
FRI0281 Cardiac valve abnormalities progression in systemic lupus erythematosus (SLE) patients detected by transthoracic and transesophageal echocardiography (TTE and TEE): 3-year follow-up
Authors: L. S. Kholopov, O. I. Dyadyk, A. E. Bagriy, O. V. Samoilova, O. V. Schukina, S. R. Zborovskyy
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Valvular heart disease is one of the most typical and prognostically significant cardiac lesions in SLE. It is not generally accepted whether valve lesions in SLE have a progressive or stable pattern [1,2]. In our prospective study we investigate dynamical changes of these abnormalities. <h3>Objectives</h3> The aim of our study was to evaluate cardiac valve lesions in SLE pts using TEE in combination with TTE during 3-year follow-up. <h3>Methods</h3> TTE was performed in 67 consecutive pts (11M:56F, mean age – 28 yrs) and TEE in 53 of them using Philips HDI 5000 with 2.0-4.0 MHz transducer and EnVisor C with multiplane 5 MHz TEE transducer. TEE was used in pts with inconclusive or controversial TIE data about valve structure [3]. <h3>Results</h3> Initially cardiac valve lesions were detected in 58 (86.6%) pts. During follow-up observation new abnormalities were revealed in 10 (14.9%) pts (see table). All new valve mass (vegetations) were diagnosed in patients with SLE exacerbation during follow-up. <h3>Conclusions</h3> During 3-year follow-up appearance or progression of cardiac valve lesions was detected totally in 18 (26.9) pts. Our data showing the dependence of valve lesion changes in SLE from immunosuppressive therapy need to be confirmed in larger studies. <h3>References</h3> <i>Leonard Wei-Ren Lan, Cheng-Ting Tsai and Charles Jia-Yin Hou. The Valvular Involvement of Lupus: Congestive Heart Failure Can Be The Presenting Feature of Systemic Lupus Erythematosus / Acta Cardiol Sin 2005;21:111-115.</i> <i>Fluture A, Chaudhari S, Frishman WH. Valvular heart disease and systemic lupus erythematosus: therapeutic implications / Heart Dis. 2003 Sep-Oct;5(5):349-53.</i> <i>Roldan CA, Qualls CR, Sopko KS, Sibbitt WL Jr. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study / J Rheumatol. 2008 Feb;35(2):224-9.</i> <b>Disclosure of Interest</b>: None Declared
Abstract 2087: Estrogen receptor beta sensitizes breast cancer cells to endoplasmic reticulum stress-regulated apoptosis
Authors: Gayani K. Rajapaksa, Fotis Nikolos, Christoforos G. Thomas, Jan-Ake Gustafsson
Journal: Cancer Research (2011)

Abstract Estrogen receptor beta (ERβ) as estrogen-regulated transcription factor is involved in the development of the normal mammary gland and affects the progression and the anti-estrogen resistance of breast cancer. Recent data connect this resistance with the activation of survival mechanisms including the unfolded protein response (UPR). The UPR assists the cells to cope with the stress induced upon accumulation of unfolded proteins in the endoplasmic reticulum (ER) named ER stress. Although estrogen receptor alpha (ERα) has been shown to alter the resistance of breast cancer cells to anti-estrogens by modulating the levels of ER stress, the role of ERβ in the regulation of the UPR has not been elucidated. Here we show that ERβ decreases the resistance of breast cancer cells to chemically-induced ER stress by altering the inositol-requiring enzyme-1 (IRE-1) pathway of the UPR. In particular, we found that induction in the expression of ERβ enhances apoptosis and upregulates the ER stress-regulated pro-apoptotic CHOP/GADD153 in MDA-MB-231 breast cancer cells in response to treatment with the ER stressor thapsigargin. ERβ induces apoptosis under ER stress by inhibiting the unconventional mRNA splicing of X-box binding protein-1 (XBP-1), and thus, attenuating the upregulation of the active transcription factor which reduces the load of unfolded proteins in the ER. These results suggest ERβ as a potential modulator of the resistance of breast cancer cells to ER stressors through regulating the UPR. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2087. doi:10.1158/1538-7445.AM2011-2087
11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT
Authors: Francesco Ceci, Riccardo Schiavina, Paolo Castellucci, Eugenio Brunocilla, Chiara Fuccio, Patrick M. Colletti, Alice Ferretti, Sotirios Chondrogiannis, Domenico Rubello, Daniele Romagnoli, Claudio Malizia, Giuseppe Martorana, Stefano Fanti
Journal: Clinical Nuclear Medicine (2013)

The purpose of this preliminary study was to evaluate the usefulness of 11C-choline PET/CT in patients with recurrent prostate cancer and hormone-sensitive disease treated with intermittent antiandrogen therapy scheme.We retrospectively evaluated 10 patients after radical prostatectomy (n = 8) or external beam radiotherapy (n = 2) as primary therapy, studied with sequential 11C-choline PET/CT. The first PET/CT (PET1) was performed during antiandrogen therapy (ADT) and the second PET/CT (PET2) was performed after therapy interruption. Only patients with negative results at PET1 were included in the study. At the time of PET1, all patients were under ADT from at least 6 months (mean PSA 0.54 ng/mL). At the time of PET2, all patients had completed ADT for a mean period of 7 months. 11C-Choline PET/CT findings were validated by a follow-up of at least 12 months or histological confirmation in case of local relapse.PET2 has been able to detect the site of recurrences in all cases. At the time of PET2, mean PSA was 3.88 ng/mL; mean PSAdt was 2.46 months; and mean PSAvel was 6.94 ng/mL/year. Four out of 10 patients showed a single lesion, 5 out of 10 patients showed 2 lesions and 1 patient showed multiple lymph-node lesions.When performed during ADT interruption, 11C-choline PET/CT has been able to detect the site of recurrence in patients with increasing PSA values. In this context, 11C-choline PET/CT may help to assess the burden of disease or to change the therapeutic approach using more aggressive and addressed therapies like guided RT or salvage lymph-node dissection.
Effects of Diets High in Sucrose or Aspartame on The Behavior and Cognitive Performance of Children
Authors: Mark L. Wolraich, Scott D. Lindgren, Phyllis J. Stumbo, Lewis D. Stegink, Mark I. Appelbaum, Mary C. Kiritsy
Journal: New England Journal of Medicine (1994)

Both dietary sucrose and the sweetener aspartame have been reported to produce hyperactivity and other behavioral problems in children.
ENHANCED REGENERATIVE EFFECT OF CARDIOSPHERE-DERIVED CELLS BY PRE-TREATMENT WITH PARACRINE FACTOR APOSEC IN PORCINE CLOSED-CHEST REPERFUSED MYOCARDIAL INFARCTION PROBED BY QUANTITATIVE CARDIAC 18F-FDG-PET-MRI
Authors: Mariann Gyongyosi, Johannes Winkler, Hendrix Ankersmit, Julia Mester-Tonczar, Andras Jakab, Katrin Zlabinger, Dominika Lukovic, Alfred Gugerell, Noemi Pavo, Georg Goliasch, James Dawkins, Eduardo Marban
Journal: Journal of the American College of Cardiology (2016)
RESECCIÓN ENDOSCÓPICA MUCOSA MEDIANTE LIGADURA EN EL TRATAMIENTO DE PACIENTES CON LESIONES PRENEOPLASICAS O NEOPLÁSICAS PRECOCES DE ESÓFAGO Y ESTÓMAGO
Authors: J Espinel, E Pinedo, R Diez, G Rascarachi, L Arias, AB Dominguez
Journal: Endoscopy (2010)

Objetivo: Valorar la eficacia y seguridad de la resección endoscópica mucosa mediante ligadura con bandasen pacientes con lesiones preneoplásicas o neoplásicas precoces de esófago y estómago (esófago de Barrett con displasia, cáncer gástrico precoz).
Late Breaking News: Commission Urges Stronger Leadership Against AIDS
Authors: R. Scott
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Late Breaking News : Commission Urges Stronger Leadership Against AIDS Get access Robert Scott Robert Scott Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 20, 16 October 1991, Page 1449, https://doi.org/10.1093/jnci/83.20.1449 Published: 16 October 1991
If I had . . .
Authors: K N Palmer
Journal: BMJ (1978)

field in an ovulatory mucus with a spinnbar- keit of more than 6 cm has been shown to have statistically significant correlation with a median sperm count of over 28 million/ml,3 and thus a positive test is of great value itself.However, lesser degrees of positivity and even negative postcoital tests are of value only when they have been repeatedly shown to be so at the time of presumptive ovulation and steps have been taken to confirm the validity of this timing.Only then are negative postcoital tests indicative of abnormality.Single and isolated tests without ancillary information are thus merely indications for further investiga- tions of the infertile couple into the multifactorial factors which are potentially related to their inability to conceive.
CORONARY MICROVASCULAR DYSFUNCTION AND CORONARY ARTERY CALCIFICATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC SCLEROSIS, AND RHEUMATOID ARTHRITIS
Authors: Kentaro Kakuta, Kaoru Dohi, Yoshiko Sato, Takashi Yamanaka, Masaki Kawamura, Shiro Nakamori, Ryuji Okamoto, Eitaro Fujii, Norikazu Yamada, Masaaki Ito
Journal: Journal of the American College of Cardiology (2015)
Abstract 5484: Childhood leukemia and lymphoma: African experience supports a role for environmental factors
Authors: Christopher K. Williams
Journal: Cancer Research (2012)

Abstract Major differences exist in the nature of leukaemia and lymphoma (Le/Ly) in low-income African children (LIAC) compared to those of high-income world (HIW). These include the absence of the peak incidence of acute lymphoblastic leukemia (ALL) in the first quinquennium (FQ) that characterizes the disease in HIW. Conversely, chloroma association with acute myelogenous leukemia (CA-AML) and Burkitt's lymphoma (BL) are rare in HIW. In 1982-1984, using standard international study protocol, we performed immunophenotypic characterisation (IPC) in 86 Le/Ly patients, including 18 &amp;lt; 15 years, 21 ≥15 years ALL patients; 6 AML, 23 chronic lymphocytic leukaemia (CLL) and 18 non-Hodgkin's lymphoma (NHL) patients. Rearrangement (GR) of immunoglobulin and T-cell receptor genes was evaluated in 19/32 samples. IPC/GR confirmed ALL subtypes as “common”: 4 (22.2%), null: 2 (11.1%), T: 7 (38.9%), B: 4 (22.2%), and 1 (5.6%) unclassifiable among ≤ 15 years and 8 (38.1%), 1(4.8%), 11 (52.4%) 1 (4.8%) and 0 (0.0%) ≥.15 years. These and other cases of Le/Ly in Ibadan/Nigeria (population &amp;gt; 2x106) were studied for spatial clustering, while the incidence (x10−5) of childhood ALL (CAL) subtypes was estimated and compared with those of contemporary populations elsewhere. Reduced incidence of CAL in Ibadan was due to depletion of c-ALL and absence of FQ-ALL, and correlated inversely with the incidence of Burkitt's lymphoma (BL) and of chloroma-associated AML (CA-AML). C-ALL predominated in low-density/higher socio-economic (SES), vis-a-vis BL and CA-AML in high-density/lower SES lifestyle areas. The aberrant response model, which has been hypothesized for the high prevalence of c-ALL in HIW may also serve to explain the opposite pathology in LIAC. It is proposed that either an identical or closely related etiological pathway is shared by all three disorders. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5484. doi:1538-7445.AM2012-5484
Chronic Cyclic Nonnephrogenic Magnesium Depletion without Losses
Authors: Luis M. Blasco, Francisco Novo, Carmen R. González-Fernández
Journal: New England Journal of Medicine (2012)

A patient with chronic weakness, muscle cramps, paresthesia, gait disturbance, somnolence, and cognitive impairment was found to be magnesium deficient. However, no source of magnesium loss could be identified. Her symptoms resolved with magnesium repletion.
Abstract 3360: Inhibition of ALDH activity prevents the maintenance and expansion of cancer stem cell-like population in a mouse model of breast cancer
Authors: Ran-Ju Kim, Jeong-Ran Park, Kyung-Jin Roh, Kyoung-Jin Nho, Soo-Rim Kim, Yoo-Kyung Lee, Jeong-Seok Nam
Journal: Cancer Research (2010)

Abstract The cancer stem cell (CSC) hypothesis proposes that CSCs are the root of cancer and cause cancer metastasis and recurrence. High activity of aldehyde dehydrogenase (ALDH) has been recognized as a marker for normal and malignant stem cells. It has been also known that ALDH activity is important for multiple biological activities including drug resistance, cell differentiation, and oxidative metabolism. In this study, we focused on the molecular mechanism of ALDH activity in CSC dynamics. To address the underlying mechanism, we have used the 4T1 mouse model of breast cancer. We found that ALDHpos cells showed a high increase of the stem cell-like properties, such as sphere forming ability, expression of stem markers, and tumor initiation ability in vivo, when compared with the counterparts. Blockade of ALDH activity suppressed these properties of CSC. Especially, the high activity of ALDH was shown to enhance CSC properties through up-regulating Oct-4 expression that is dependent on oxygen-related transcription factor. Therefore, these findings suggest that the selective targeting of ALDH activity may be useful for stem specific cancer therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3360.